2021 ADA/EASD共识报告:1型糖尿病患者的管理

2021-09-30 美国糖尿病学会 Diabetologia

2021年9月,美国糖尿病学会(ADA)联合欧洲糖尿病研究协会(EASD)共同发布了1型糖尿病患者管理共识。

中文标题:

2021 ADA/EASD共识报告:1型糖尿病患者的管理

英文标题:

The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

发布机构:

美国糖尿病学会

发布日期:

2021-09-30

简要介绍:

2021年9月,美国糖尿病学会(ADA)联合欧洲糖尿病研究协会(EASD)共同发布了1型糖尿病患者管理共识。主要内容涉及1型糖尿病患者的初步评估和治疗、成人1型糖尿病患者的血糖管理目标、血糖管理的一般原则、1型糖尿病疑似人群的管理流程图、1型糖尿病的辅助治疗方案(二甲双胍、普林兰肽、GLP-1RA、SGLT-2i)、β细胞替代疗法适应证、胰岛素和血糖监测策略的选择等,

相关资料下载:
[AttachmentFileName(sort=1, fileName=Holt2021_Article_TheManagementOfType1DiabetesIn.pdf)] GetToolGuiderByIdResponse(projectId=1, id=052521c0021998f0, title=2021 ADA/EASD共识报告:1型糖尿病患者的管理, enTitle=The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), guiderFrom=Diabetologia, authorId=0, author=, summary=2021年9月,美国糖尿病学会(ADA)联合欧洲糖尿病研究协会(EASD)共同发布了1型糖尿病患者管理共识。, cover=https://img.medsci.cn/2021104/1633320271460_5579292.jpg, journalId=0, articlesId=null, associationId=54, associationName=美国糖尿病学会, associationIntro=美国糖尿病协会县美国重要的非赢利性卫生姐织,旨在提供有关糖尿病的研究进展和信息,促进糖尿病的科研、教育、诊疗等,关注一切与糖尿病有关的事务。协会成立千 1940年,以预防和治疗糖尿病,改善所有糖尿病患者生活质量为目标。一年一度的全球糖尿病领域最大规模的盛会&mdash;&mdash;美国糖尿病协会(ADA)年会于每年的6月如期而至,每年将有来自世界各地的13000名研究者、医生及其他专业人士莅临,共同分享糖尿病领域前沿研究、治疗建议以及治疗新趋势,聚焦糖尿病领域基础研究与临床实践的最新进展,公布最新临床试验结果,关注如何将研究成果应用于临床实践。, copyright=0, guiderPublishedTime=Thu Sep 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年9月,美国糖尿病学会(ADA)联合欧洲糖尿病研究协会(EASD)共同发布了1型糖尿病患者管理共识。主要内容涉及1型糖尿病患者的初步评估和治疗、成人1型糖尿病患者的血糖管理目标、血糖管理的一般原则、1型糖尿病疑似人群的管理流程图、1型糖尿病的辅助治疗方案(二甲双胍、普林兰肽、GLP-1RA、SGLT-2i)、&beta;细胞替代疗法适应证、胰岛素和血糖监测策略的选择等,</p> </div> </div> </div>, tagList=[TagDto(tagId=2054, tagName=1型糖尿病)], categoryList=[CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2054, guiderKeyword=1型糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13735, appHits=147, showAppHits=0, pcHits=887, showPcHits=13588, likes=0, shares=15, comments=7, approvalStatus=1, publishedTime=Mon Oct 04 12:07:56 CST 2021, publishedTimeString=2021-09-30, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Oct 04 12:07:51 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 20:36:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=Holt2021_Article_TheManagementOfType1DiabetesIn.pdf)])
Holt2021_Article_TheManagementOfType1DiabetesIn.pdf
下载请点击:
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1218195, encodeId=4ce0121819590, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Mon May 09 15:08:54 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193972, encodeId=368711939e2aa, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4a2211139, createdName=嗷呜呜1233, createdTime=Wed Feb 16 11:42:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071301, encodeId=06b610e130111, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc84090633, createdName=阳阳医生, createdTime=Thu Nov 18 08:57:57 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057762, encodeId=4d08105e76231, content=还好还好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:12 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057761, encodeId=e508105e7610d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:07 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2022-05-09 356947897

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1218195, encodeId=4ce0121819590, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Mon May 09 15:08:54 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193972, encodeId=368711939e2aa, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4a2211139, createdName=嗷呜呜1233, createdTime=Wed Feb 16 11:42:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071301, encodeId=06b610e130111, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc84090633, createdName=阳阳医生, createdTime=Thu Nov 18 08:57:57 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057762, encodeId=4d08105e76231, content=还好还好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:12 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057761, encodeId=e508105e7610d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:07 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2022-02-16 嗷呜呜1233

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1218195, encodeId=4ce0121819590, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Mon May 09 15:08:54 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193972, encodeId=368711939e2aa, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4a2211139, createdName=嗷呜呜1233, createdTime=Wed Feb 16 11:42:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071301, encodeId=06b610e130111, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc84090633, createdName=阳阳医生, createdTime=Thu Nov 18 08:57:57 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057762, encodeId=4d08105e76231, content=还好还好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:12 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057761, encodeId=e508105e7610d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:07 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2021-11-18 阳阳医生

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1218195, encodeId=4ce0121819590, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Mon May 09 15:08:54 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193972, encodeId=368711939e2aa, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4a2211139, createdName=嗷呜呜1233, createdTime=Wed Feb 16 11:42:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071301, encodeId=06b610e130111, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc84090633, createdName=阳阳医生, createdTime=Thu Nov 18 08:57:57 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057762, encodeId=4d08105e76231, content=还好还好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:12 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057761, encodeId=e508105e7610d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:07 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2021-10-05 微探

    还好还好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1218195, encodeId=4ce0121819590, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22934661794, createdName=356947897, createdTime=Mon May 09 15:08:54 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193972, encodeId=368711939e2aa, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4a2211139, createdName=嗷呜呜1233, createdTime=Wed Feb 16 11:42:07 CST 2022, time=2022-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1071301, encodeId=06b610e130111, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cc84090633, createdName=阳阳医生, createdTime=Thu Nov 18 08:57:57 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057762, encodeId=4d08105e76231, content=还好还好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:12 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057761, encodeId=e508105e7610d, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Oct 05 07:59:07 CST 2021, time=2021-10-05, status=1, ipAttribution=)]
    2021-10-05 微探

    学习学习

    0

拓展阅读

2015 JDRF/TES/ADA科学声明:1型糖尿病的前驱症状

美国糖尿病学会(ADA,American Diabetes Association) · 2015-09-20

2017 共识声明:1型糖尿病的运动管理

国外内分泌相关专家小组(统称) · 2017-05-01

2018 ISPAD临床实践共识指南:儿童和青少年1型糖尿病的分期

国际儿童青少年糖尿病协会(ISPAD,International Society for Pediatric and Adolescent Diabetes) · 2018-07-26

2018 ADA立场声明:儿童和青少年1型糖尿病

美国糖尿病学会(ADA,American Diabetes Association) · 2018-08-09

2018 ISPAD临床实践指南:儿童和青少年囊性纤维化相关性糖尿病的管理

国际儿童青少年糖尿病协会(ISPAD,International Society for Pediatric and Adolescent Diabetes) · 2018-08-09